Maharashtra FDA suspends food licence of Blinkit dark store in Pune
Maharashtra's Food and Drug Administration (FDA) has suspended the food licence of
quick commerce
platform
Blinkit
in
Pune
's Balewadi area for not complying with regulations.
This comes after the authorities stepped up surveillance of dark stores amid concerns around food safety and hygiene in these facilities.
The Maharashtra FDA conducted an investigation on June 5 and found that the facility did not have a licence from the Food Safety and Standards Authority of India for production, distribution or sale of food items.
Following this, the facility's food business licence was suspended until the required licence under Section 31 (1) of the Food Safety and Standards Act, 2006, is obtained.
Despite the lack of a licence, the Blinkit facility, operated by M/s Energy Darkstore Services near Mitcon College in Balewadi, was storing and selling food items.
Blinkit did not respond to detailed queries on the matter.
Discover the stories of your interest
Blockchain
5 Stories
Cyber-safety
7 Stories
Fintech
9 Stories
E-comm
9 Stories
ML
8 Stories
Edtech
6 Stories
In the same order, the authorities noted that the facility had also violated food safety measures. They found food items on the floor, the pest control audit certificate missing, workers in the food area not wearing protective caps, food items stored on dusty racks and a cold storage without a calibration certificate.
Last week, a similar probe was conducted at quick commerce platform
Zepto's Dharavi facility
and its food business licence was suspended after it was found to be in violation of food safety guidelines. The violations included fungal growth on food articles, food storage near stagnant water, the cold storage temperature not being maintained and expired food items unsegregated from the main stock, as per a press note by the FDA.
Also Read:
Concerns rise over hygiene standards in dark stores amid quick commerce boom
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
an hour ago
- The Hindu
New ‘weight-loss' drugs have lower impact in real life compared to clinical trial results: study
A recent study done in the U.S. showed that semaglutide and tirzepatide — injectable GLP-1 drugs for obesity — produce lower weight loss in a real-world setting, than during the clinical trial, because patients discontinue treatment or use lower maintenance dosages. The results were published by researchers from the Cleveland Clinic, Ohio, U.S., in the peer-reviewed journal Obesity on June 10. Semaglutide and tirzepatide are FDA-approved medications for the treatment of type 2 diabetes and chronic weight management and are now also available in India. Hamlet Gasoyan et al accessed electronic health record data from a large health system in Ohio and Florida to identify adults with overweight or obesity without type 2 diabetes who started with injectable semaglutide or tirzepatide between 2021 and 2023. They recorded early discontinuation (within 3 months) and late discontinuation (within 3–12 months) along with weight reduction. The researchers observed that treatment discontinuation and use of lower maintenance dosages might reduce the likelihood of achieving clinically-meaningful weight reduction in patients on these drugs. Researchers also identified the factors associated with higher odds of achieving a weight loss of 10% or more, after one year of treatment — continuing medications or discontinuing late (vs. early), taking a high maintenance dosage, getting tirzepatide (vs. semaglutide) and were female (vs. male). Commenting on the results of the study, V. Mohan, senior diabetologist, and chairman, Dr. Mohan's Diabetes Specialties Centre, Chennai, who has initiated patients on weight-loss drugs, says: 'The findings are not surprising because in a randomised clinical trial (RCT), there is constant follow up with the participants to continue with the drug regimen. On the other hand, in the real world, especially if patients buy their own medication, they often stop the drug. Even otherwise, compliance rates in real world are much poorer than in an RCT. The bottom line is that these drugs work as long as they are taken. That is how it is with most drugs, if you stop statins, for instance, cholesterol levels go up; if you stop anti-diabetic drugs or BP drugs, the sugar and BP go up.' 'A reality check' Anoop Misra, who heads Fortis C-DOC Hospital for Diabetes and Allied Sciences in Delhi, who has also put his patients on these class of drugs, says: 'This study gives us a reality check of weight loss and blood sugar lowering effects of these drugs. It is important to note that discontinuation of such drugs is likely to be more in India, driven also by cost concerns. Non-compliance to diet and exercise are additional reasons to be considered in India which may cause lower weight loss.' 'Our findings about the real-world use patterns of these medications and associated clinical outcomes could inform the decisions of healthcare providers and their patients on the role of treatment discontinuation and maintenance dosage in achieving clinically meaningful weight reductions,' said Dr. Gasoyan.
Mint
4 hours ago
- Mint
BigBasket plans to launch 10-minute food delivery by March 2026 to compete with quick commerce rivals
The Tata Group-backed online e-commerce platform BigBasket plans to launch its 10-minute food delivery services across India by the end of the financial year 2025-26, to compete against other quick commerce rivals in the Indian market, reported the news agency Reuters, citing co-founder Vipul Parekh. According to the agency report, the grocery giant is planning to take on Swiggy's Snacc, Blinkit's Bistro and Zepto Cafe, which are currently delivering food and snack items to consumers in less than 15 minutes. The co-founder told the agency that the company aims to target the customer base of other firms like Swiggy and Zomato while also accessing a new pool of customers. As companies shift to the booming quick commerce industry, big firms like Blinkit, Swiggy, Flipkart, and Zepto are already competing against each other to capture higher market share. BigBasket also plans to use dark stores to roll out its upcoming 10-minute food delivery services. The small warehouses, which are used to store the items required for the delivery, are also known as a 'dark store' where riders show up with their two-wheelers to pick up groceries or food for the delivery to the designated customer. The company plans to expand its dark store operations to 1,000-1,200 stores by the end of 2025, compared to its current level of 700 stores across the nation, according to the agency report. BigBasket reportedly launched its pilot food delivery service in Bengaluru one month ago and now plans to expand its operations to 40 dark stores by the end of July 2025, according to the agency report, citing the co-founder. Vipul Parekh, the co-founder of BigBasket, is now in charge of the company's marketing and finance functions, according to his LinkedIn profile. Data shows that 5 to 10 per cent of BigBasket's customers are opting to combine quick-food items with their normal online orders. The company expects this number to further rise in the upcoming time period, as per the news report. Customers using this facility will be able to access Starbucks to Qmin, both Tata Group's coffee and food businesses. According to the news agency's report, no other restaurants will be partnered with the quick commerce service. However, the co-founder rejected the claims of BigBasket seeking external investors for fundraising and said that the company reportedly plans to go public in the next 18 to 24-month period. 'One of the advantages we have is, being a part of Tata Group, you have enough internal capital available,' said Parekh, cited in the news agency's report.
Economic Times
5 hours ago
- Economic Times
Two Sharp with ET: Food safety shock hits Blinkit, Zepto; rare-earth crisis rattles auto sector
Zomato's Blinkit and Zepto are under fire as FDA raids expose expired goods and hygiene issues, shaking investor confidence. Meanwhile, a rare-earth export squeeze from China halts car production at Ford and Suzuki. India faces food safety fears at home and supply chain tremors abroad. All of this in today's Two Sharp with ET. Show more 05:49 04:16 06:46 07:02 02:22 01:20 05:13 04:31 02:05 02:05 04:06 06:16 01:28 07:08 01:38 04:40 03:48 02:17 06:32 01:25 02:35 04:55 06:21 04:31 01:40 06:04 05:39 07:05 02:22 05:26 01:45 02:41 02:40 01:29 05:00 03:14 04:45 06:38 01:11 04:28
